Tocilizumab (Actemra)

OFFICE ADMINISTRATION / SELF-INJECTION

Indications for Prior Authorization:

  • Moderate to severe rheumatoid arthritis
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA)
  • Systemic Juvenile Idiopathic Arthritis (SJIA)

Patients must meet the following criteria for the indications above:

Rheumatoid Arthritis (moderate to severe)

  • Diagnosed by rheumatologist (prescriber does not have to be rheumatologist)
  • ONE of the following:
    • Inadequate response or intolerance to at least one Disease Modifying Anti-Rheumatic Drug (DMARDs):
      • auranofin (Ridaura®)
      • azathioprine (Imuran®)
      • cyclosporine (Neoral®)
      • hydroxychloroquine (Plaquenil®)
      • methotrexate (Rheumatrex®)
      • D-penicillamine (Cuprimine®)
      • sulfasalazine (Azulfidine®)
      • leflunomide (Arava®)
    • Has medical justification why methotrexate, hydroxychloroquine, and sulfasalazine cannot be used
    • Inadequate response or intolerable side effects to two of the following: adalimumab (Humira), etanercept (Enbrel) or infliximab (Remicade)

Polyarticular Juvenile Idiopathic Arthritis

  • Diagnosis of polyarticular juvenile idiopathic arthritis (PJIA), AND
  • Diagnosed by a Rheumatologist (the prescribing physician does not have to be a Rheumatologist), AND
  • Patient is 2 years of age or older, AND
  • Inadequate response, intolerance , or contraindication to methotrexate, AND
  • Inadequate response or intolerable side effect to Enbrel and Humira

Systemic Juvenile Idiopathic Arthritis (SJIA)/Still’s Disease

  • Diagnosis of systemic juvenile idiopathic arthritis (SJIA)/Still’s disease, AND
  • Diagnosed by a Rheumatologist (the prescribing physician does not have to be a Rheumatologist), AND
  • Patient is 2 years of age or older

Dosing:

Rheumatoid Arthritis

  • Intravenous Infusion: 4 mg/Kg is given by IV infusion over 60 minutes every four weeks
  • The dose may be increased to 8 mg/Kg based on clinical response.  Actemra doses exceeding 800 mg per infusion are not recommended in RA patients

Subcutaneous self-administration

  • For patients <100kg: Initial to 162 mg SubQ every other week. May increase to 162 mg SubQ based on clinical response
  • For patients ≥100kg: up to 162 mg SubQ weekly

Polyarticular Juvenile Idiopathic Arthritis

  • Up to 10mg/kg IV infusion as often as every 4 weeks at the following dose:
Patient Wt Maximum Dose
< 30kg  10mg/kg
> 30kg 8mg/kg

 

Systemic Juvenile Idiopathic Arthritis (SJIA)/Still’s Disease

  • Up to 12mg/kg IV infusion as often as every 2 weeks at the following dose:
Patient Wt Maximum Dose
< 30kg  12mg/kg
> 30kg  8mg/kg

 

Tocilizumab should not be initiated in patients with an absolute neutrophil count (ANC)

  • Below 2000/mm3, platelet count below 100,000/mm3, OR
  • Who have ALT or AST above 1.5 times the normal range

Tocilizumab may be used alone or in combination with methotrexate or other disease modifying anti-rheumatic drugs (DMARDs)

Approval:

  • Initial: six months to assess patient’s response
  • Renewal: one year if patient has clinical response
  • Risk of Tuberculosis and Serious Infection
  • Patients should be evaluated for latent tuberculosis infection with a TB skin test. Treatment of latent tuberculosis infection should be initiated prior to therapy with golimumab
  • Do not administer live vaccines or attenuated vaccines concurrently with golimumab
  • Patients should be routinely monitored for elevated liver enzymes, elevated low-density lipoprotein (LDL), hypertension, and gastrointestinal perforations

 

Last review date: July 20, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.